Additionally, Postow et al. showed that increased TCR repertoire and T cell diversity in peripheral blood of 12 melanoma patients before anti-CTLA-4 therapy was associated with clinical benefit (Postow et al. 2015). The gene discussed is CTLA4; the disease is melanoma.